Notice of Annual General Meeting of Vitrolife AB (publ)

The Annual General Meeting of Vitrolife AB (publ) will take place on Thursday
April 28, 2016, at 5 p.m. in the company’s premises at Gustaf Werners gata 2 in
Gothenburg. Notice of attendance at the Annual General Meeting shall be given no
later than Friday, April 22, 2016.
Shareholders wishing to participate at the Annual General Meeting shall notify
the company by mail to Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg,
Sweden, Att: Anita Ahlqvist, by phone +46 31 721 80 83, by fax +46 31 721 80 99
or by e-mail aahlqvist@vitrolife.com. Full name/business name, preferably
personal identification number/ company registration number (or the equivalent),
address, telephone number, number of shares, details of any advisors and where
appropriate details of a representative or proxy must be stated in the
notification. A proxy form in Swedish for shareholders wishing to be represented
by proxy will be found on www.vitrolife.com.

Shareholders that have their shares registered in the name of a nominee must
temporarily record their shares in the share register kept by Euroclear Sweden
AB in their own names to be able to attend the General Meeting. Such
registration must be carried out no later than Friday, April 22, 2016.

The following proposals will be amongst those presented at the Annual General
Meeting:

  · Dividend of SEK 2.40 per share and Monday, May 2, 2016, as the record date
for the dividend.

  · The Election Committee proposes that the Board shall consist of six members.
The Election Committee proposes re-election of Carsten Browall, Barbro Fridén,
Tord Lendau, Pia Marions, Fredrik Mattsson and Jón Sigurdsson. It is proposed
that Carsten Browall is elected as Chairman of the Board (re-election).
Remuneration to the Board members is proposed to be SEK 1,615,000, of which SEK
500,000 to the Chairman of the Board, SEK 175,000 to each of the other members
of the Board. SEK 60,000 to the Chairman of the Audit Committee, SEK 60,000 to
the Chairman of the Remuneration Committee and SEK 30,000 to the other members
of these committees. The proposal equals an increase of SEK 175,000 of the
total amount compared to the previous year.

  · Authorization for the Board to resolve to issue new shares up until the next
Annual General Meeting.

  · Authorization for the Board to make a decision on the acquisition of the
company’s own shares during the period up until the next Annual General Meeting.

Attachment: Full notice

Gothenburg, March 22, 2016
VITROLIFE AB (publ)
The Board
Contact:
Carsten Browall, Chairman of the Board, phone 46 70 255 65 32
Mikael Engblom, CFO, phone 46 31 721 80 14

Vitrolife is required to publish the information in this press release in
accordance with the Swedish Securities Market Act and/or the Financial
Instruments Trading Act. The information was submitted for publication on March
22, 2016 at 11:00 a.m.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.
________________________________________________________________________________
_ 
________________________________

Vitrolife is an international medical device Group. Vitrolife develops, produces
and markets medical devices for assisted reproduction. Work is also carried out
to enable the use and handling of stem cells for therapeutic purposes

Vitrolife has approximately 330 employees and the company's products are sold
in about 110 markets. The company is headquartered in Gothenburg, Sweden, and
there are also offices in USA, Australia, France, Italy, United Kingdom, China,
Japan, Hungary and Denmark. The Vitrolife share is listed on NASDAQ OMX
Stockholm, Mid Cap.

Vitrolife AB (publ), Box 9080, SE-400 92 Göteborg, Sweden. Corporate identity
number 556354-3452. Tel: 46 31 721 80 00. Fax: 46 31 721 80 99. E-mail:
info@vitrolife.com. Website: www.vitrolife.com/